211 related articles for article (PubMed ID: 27685445)
1. FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
Marzi L; Combes E; Vié N; Ayrolles-Torro A; Tosi D; Desigaud D; Perez-Gracia E; Larbouret C; Montagut C; Iglesias M; Jarlier M; Denis V; Linares LK; Lam EW; Martineau P; Del Rio M; Gongora C
Br J Cancer; 2016 Nov; 115(10):1223-1233. PubMed ID: 27685445
[TBL] [Abstract][Full Text] [Related]
2. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
4. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.
Derer S; Berger S; Schlaeth M; Schneider-Merck T; Klausz K; Lohse S; Overdijk MB; Dechant M; Kellner C; Nagelmeier I; Scheel AH; Lammerts van Bueren JJ; van de Winkel JG; Parren PW; Peipp M; Valerius T
Neoplasia; 2012 Mar; 14(3):190-205. PubMed ID: 22496619
[TBL] [Abstract][Full Text] [Related]
6. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
7. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L
Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520
[No Abstract] [Full Text] [Related]
8. EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer.
Atkinson CJ; Kawamata F; Liu C; Ham S; Győrffy B; Munn AL; Wei MQ; Möller A; Whitehall V; Wiegmans AP
Mol Oncol; 2019 Apr; 13(4):725-737. PubMed ID: 30478887
[TBL] [Abstract][Full Text] [Related]
9. Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells.
Yang LJ; Tang Q; Wu J; Chen Y; Zheng F; Dai Z; Hann SS
J Exp Clin Cancer Res; 2016 Mar; 35():59. PubMed ID: 27036874
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38α modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A.
Germani A; Matrone A; Grossi V; Peserico A; Sanese P; Liuzzi M; Palermo R; Murzilli S; Campese AF; Ingravallo G; Canettieri G; Tezil T; Simone C
Cancer Lett; 2014 Mar; 344(1):110-118. PubMed ID: 24215867
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
12. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
[TBL] [Abstract][Full Text] [Related]
13. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
14. Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells.
Kundu S; Ali MA; Handin N; Padhan N; Larsson J; Karoutsou M; Ban K; Wiśniewski JR; Artursson P; He L; Hellström M; Sjöblom T
Genome Med; 2018 Jan; 10(1):2. PubMed ID: 29301589
[TBL] [Abstract][Full Text] [Related]
15. Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin.
Narvi E; Vaparanta K; Karrila A; Chakroborty D; Knuutila S; Pulliainen A; Sundvall M; Elenius K
Sci Rep; 2018 Nov; 8(1):16579. PubMed ID: 30410004
[TBL] [Abstract][Full Text] [Related]
16. Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a.
Zhang L; Yang X; Li X; Li C; Zhao L; Zhou Y; Hou H
Int J Mol Med; 2015 Oct; 36(4):957-66. PubMed ID: 26310353
[TBL] [Abstract][Full Text] [Related]
17. T63, a new 4-arylidene curcumin analogue, induces cell cycle arrest and apoptosis through activation of the reactive oxygen species-FOXO3a pathway in lung cancer cells.
Liu H; Zhou BH; Qiu X; Wang HS; Zhang F; Fang R; Wang XF; Cai SH; Du J; Bu XZ
Free Radic Biol Med; 2012 Dec; 53(12):2204-17. PubMed ID: 23085518
[TBL] [Abstract][Full Text] [Related]
18. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
[TBL] [Abstract][Full Text] [Related]
19. Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer.
Knickelbein K; Tong J; Chen D; Wang YJ; Misale S; Bardelli A; Yu J; Zhang L
Oncogene; 2018 Aug; 37(33):4599-4610. PubMed ID: 29755130
[TBL] [Abstract][Full Text] [Related]
20. SP1 upregulated FoxO3a promotes tumor progression in colorectal cancer.
Yu Y; Peng K; Li H; Zhuang R; Wang Y; Li W; Yu S; Liang L; Xu X; Liu T
Oncol Rep; 2018 May; 39(5):2235-2242. PubMed ID: 29565456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
